Bolt Biotherapeutics (BOLT) Net Income towards Common Stockholders (2020 - 2025)
Historic Net Income towards Common Stockholders for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to -$7.2 million.
- Bolt Biotherapeutics' Net Income towards Common Stockholders rose 5238.53% to -$7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.8 million, marking a year-over-year increase of 3859.66%. This contributed to the annual value of -$67.8 million for FY2024, which is 202.9% up from last year.
- Bolt Biotherapeutics' Net Income towards Common Stockholders amounted to -$7.2 million in Q3 2025, which was up 5238.53% from -$8.6 million recorded in Q2 2025.
- In the past 5 years, Bolt Biotherapeutics' Net Income towards Common Stockholders registered a high of -$7.2 million during Q3 2025, and its lowest value of -$27.2 million during Q4 2021.
- Its 5-year average for Net Income towards Common Stockholders is -$18.1 million, with a median of -$18.0 million in 2023.
- Per our database at Business Quant, Bolt Biotherapeutics' Net Income towards Common Stockholders plummeted by 11326.52% in 2021 and then surged by 5937.25% in 2025.
- Over the past 5 years, Bolt Biotherapeutics' Net Income towards Common Stockholders (Quarter) stood at -$27.2 million in 2021, then increased by 26.37% to -$20.0 million in 2022, then rose by 10.47% to -$17.9 million in 2023, then rose by 10.99% to -$15.9 million in 2024, then skyrocketed by 54.66% to -$7.2 million in 2025.
- Its Net Income towards Common Stockholders stands at -$7.2 million for Q3 2025, versus -$8.6 million for Q2 2025 and -$11.1 million for Q1 2025.